Skip to main content
. Author manuscript; available in PMC: 2017 Apr 5.
Published in final edited form as: Vaccine. 2011 Feb 22;29(17):3293–3298. doi: 10.1016/j.vaccine.2011.02.021

Table 2.

Variation in lots of Oka/GSK and Oka/Merck.

SNPa ORF P-Okab Oka/GSK lotsc,e
Oka/Merck lotsd,e
A B C D E 1 2 3 4 5
560 5′ non-cod T 0 0 0 0 0 0 0 0 0 0
19431 14 T 61 57 57 57 64 79 81 80 85 83
58595 (530) 31 A 71 67 67 68 78 45 46 48 47 49
87280 50 A 100 84 80 74 100 100 85 85 85 87
89734 51 A 24 25 25 25 19 100 100 100 100 100
97748 (585) 55 G 45 56 50 58 30 61 56 64 67 60
105169 61/62 A 50 21 21 21 61 56 50 53 53 51
105356 (1260) 62 T 13 6 0 0 0 34 36 31 33 31
105705 62 T 11 0 0 0 0 51 0 0 0 0
105724 (1137) 62 A 100 100 100 100 100 93 81 82 81 100
106262 (958) 62 T 0 0 0 0 0 0 0 0 0 0
107136 62 T 40 0 32 33 0 50 50 48 48 46
107252 (628) 62 T 0 0 0 0 0 0 0 0 0 0
107797 (446) 62 A 69 55 56 55 55 70 75 68 68 68
108838 (99) 62 A 100 60 60 63 60 100 76 75 77 75
a

Numbers refer to the nucleotide position in Dumas; numbers in parenthesis refer to the affected amino acid residue within a particular ORF.

b

P-Oka bases are identical to those in Dumas at every position; P-Oka sequence is from Gomi et al. [7].

c

Oka/GSK-A was analysed by CSA, Oka/GSK-B, -C & -D were analysed by pyrosequencing.

d

Oka/Merck-1 was analysed by CSA, Oka/Merck-2, -3, -4 & -5 were analysed by pyrosequencing.

e

Numbers refer to the percentage wild-type allele.